DENVER, April 13 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation , a worldwide developer and marketer of diagnostic test kits, including innovative products for emerging pathogens and lethal viruses, today announced a major extension of the collaborative effort to combat important viral diseases.
“We expect this study will result in specific, cost-effective and easy to use tests for Ebola and Marburg virus detection,” said Jon Geske, Ph.D., Corgenix Project Director and Principal Investigator of the program. “In addition, the resulting diagnostics will be critical for development of vaccines and other treatments for these currently incurable diseases.”
“We are extremely pleased to have received this NIH grant, expanding our collaborative research to include the filoviruses,” said Douglass Simpson, Corgenix President and CEO. “Building on our very successful Lassa virus program, this will enable the development of state-of-the-art diagnostic tests for Ebola and Marburg viruses on multiple delivery platforms.”
Robert Garry, Ph.D., Professor of Microbiology and Immunology at the Tulane University School of Medicine, added, “We have been very pleased with the results of our collaborative effort over the past five years. The diagnostic products for Lassa have shown to be remarkably effective in clinical settings in Africa and will have a meaningful impact on the healthcare in that part of the world, and will also fill a critical gap in bioterrorism defense. Now, under the new NIH grant, we will expand this program to address these additional infectious agents that have the potential to kill hundreds of thousands of people and are of concern to the public health and bioterrorism preparedness communities.”
About Tulane University
Tulane University (New Orleans) was founded in 1834. Tulane is one of the most highly regarded and selective research universities in the United States, and is a member of the prestigious Association of American Universities. Tulane’s schools and colleges offer undergraduate, graduate and professional degrees in the liberal arts, science and engineering, architecture, business, law, social work, medicine and public health and tropical medicine.
About Autoimmune Technologies, LLC
Autoimmune Technologies (New Orleans) is a privately held biomedical company. It has licensed several breakthrough research discoveries from Tulane University School of Medicine and has made exciting discoveries of its own. Autoimmune is working to offer new diagnostic tests and new anti-viral therapeutics to the medical community based on this proprietary research.
CONTACT: William Critchfield, Senior VP and CFO of Corgenix Medical Corp.,
+1-303-453-8903, wcritchfield@corgenix.com; or Dan Snyders, Vice President,
Public Relations Supervisor of Armada Medical Marketing, +1-303-623-1190,
ext. 230, dan@armadamedical.com, for Corgenix Medical Corp.
